Prospective, open‐label, comparative study of clindamycin 1%/benzoyl peroxide 5% gel with adapalene 0.1% gel in Asian acne patients: efficacy and tolerability

Ko, Hyun Chang; Song, Margaret; Seo, Sang-Hee; Oh, Chang‐Keun; Kwon, Kyung‐Sool; Kim, M. B.

doi:10.1111/j.1468-3083.2008.02920.x

Cited by 24 publications

(21 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There may be a higher incidence of ADRs in Asian populations, including Japanese patients, of whom < 1% are of white heritage. Similar safety trends identified in this study have been reported indirectly . However, it is reported that the Asian skin type, including that of Japanese heritage, has the weakest barrier properties and the lowest degree of maturation compared with that of white and African American people .…”

Section: Discussionsupporting

confidence: 90%

Clindamycin phosphate 1·2%-benzoyl peroxide 3·0% fixed-dose combination gel has an effective and acceptable safety and tolerability profile for the treatment of acne vulgaris in Japanese patients: a phase III, multicentre, randomised, single-blinded, acti

et al. 2015

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 90%

Clindamycin phosphate 1·2%-benzoyl peroxide 3·0% fixed-dose combination gel has an effective and acceptable safety and tolerability profile for the treatment of acne vulgaris in Japanese patients: a phase III, multicentre, randomised, single-blinded, acti

et al. 2015

View full text Add to dashboard Cite

show abstract

“…While controversies still exist regarding ethnic differences in skin sensitivity, increased susceptibility to irritations has been noted by previous reports when applying topical anti-acne agents to Asian patients. [9][10][11] Asian skin has also proved more sensitive to stripping than Caucasian skin, 18 with easily altered barrier function of the stratum corneum by external stimuli. Korean dermatologists often experience that maintaining patients' adherence to prescribed topical anti-acne agents was sometimes quite challenging.…”

Section: < Application Methods >mentioning

confidence: 99%

Do tutorials on application method enhance adapalene–benzoyl peroxide combination gel tolerability in the treatment of acne?

Kwon

Park

Yoon

et al. 2015

The Journal of Dermatology

View full text Add to dashboard Cite

Fixed-dose combination adapalene 0.1% and benzoyl peroxide 2.5% gel (A-BPO) has rarely been studied for Asian acne patients, while they have complained of local irritations more often when applying individual components. In this study, we compared A-BPO gel with benzoyl peroxide (BPO) in terms of efficacy and tolerability in Korean patients first, and assessed the clinical benefit of a dermatological tutorial on application technique in reducing irritations for A-BPO. This study was conducted as a single-blind controlled split-face trial for a 12-week period. Each half facial side of 85 patients was randomly assigned to either A-BPO or BPO. Success rate, lesion counts and safety profiles were evaluated (analysis I). During initial assignment, all patients were further randomized to either dermatological tutorial (DT) or non-tutorial (NT) subgroups depending on the presence of dermatologists' tutorials for application methods to their A-BPO sides. Clinical data of the A-BPO side was compared between two subgroups (analysis II). As a result, A-BPO gel outperformed BPO, demonstrating better efficacy in success rates and lesion counts as early as 1 week. However, A-BPO proved significantly less tolerable compared with both BPO and previous A-BPO data from Caucasians. Bioengineering measurements further confirmed clinical data (analysis I). The DT subgroup achieved much better tolerability with comparable therapeutic efficacies compared with the NT subgroup (analysis II). In conclusion, A-BPO demonstrated higher efficacies in acne compared with BPO in Korean patients, while skin irritation levels were notable concurrently. Dermatologists' education for application methods would significantly decrease these side-effects, maintaining superior efficacy levels.

show abstract

“…27 The TOA-NIL25 was shorter for clindamycin/BPO than for adapalene in two out of three studies (1Á0 vs. 2Á6 weeks and 2Á9 vs. 4Á0 weeks). 30 A clindamycin/BPO combination with or without dimethicone needed a comparable time to reduce NIL by 25% (4Á7 vs. 5Á1 weeks). 30 A clindamycin/BPO combination with or without dimethicone needed a comparable time to reduce NIL by 25% (4Á7 vs. 5Á1 weeks).…”

Section: Combination Therapies Vs Monotherapiesmentioning

confidence: 95%

“…The combination therapy was superior to the monotherapy in two trials (TOA-IL25, 2Á6 vs. 6Á5 weeks and 1Á6 vs. 3Á8 weeks). 30 26,27 A shorter TOA-IL25 was seen for the combination therapy clindamycin/BPO compared with adapalene 0Á1% in two studies (0Á8 vs. 1Á6 weeks and 1Á1 vs. 4Á6 weeks), 28,29 whereas one study showed no difference (0Á5 vs. 0Á6 weeks).…”

Section: Combination Therapies Vs Monotherapiesmentioning

confidence: 99%

Systematic review on the rapidity of the onset of action of topical treatments in the therapy of mild-to-moderate acne vulgaris

et al. 2014

View full text Add to dashboard Cite

The time until a patient achieves a relevant improvement during the treatment of a skin disease is important for selecting a therapy, but has been largely neglected in reviews and guidelines. The aim of this systematic review was to determine the time until the onset of action (TOA) of topical acne treatments. The primary outcome was the TOA defined as the time until a 25% reduction in the mean number of inflammatory lesions had been achieved. A systematic literature search in Medline and Embase was carried out. Clinical trials that evaluated head-to-head comparisons of treatments in patients suffering from mild-to-moderate papulopustular acne were included. Abstract and full-text screening and data extraction were done independently by two investigators. With respect to inflammatory lesions, different concentrations of benzoyl peroxide (BPO) or adapalene did not seem to influence the TOA. BPO seemed to act more quickly than isotretinoin and tretinoin. Adapalene showed a shorter TOA than isotretinoin. Conflicting results were seen when comparing adapalene with tretinoin, with a tendency for adapalene to be faster. Clindamycin/BPO seemed to act more quickly than adapalene. Inconsistent results were seen for the comparison of clindamycin/BPO and BPO alone with a slight indication of a shorter TOA for clindamycin/BPO. Adapalene/BPO and clindamycin/BPO showed comparable TOA. When interpreting the data, the different study designs and the limited study quality need to be taken into account. Further research is needed to identify treatments that offer an early onset of action and possibly help to optimize patients' adherence. TOA should be considered as an additional outcome in acne trials.

show abstract

Prospective, open‐label, comparative study of clindamycin 1%/benzoyl peroxide 5% gel with adapalene 0.1% gel in Asian acne patients: efficacy and tolerability

Abstract: Combination formulation of CDP/BPO and ADA were shown to be both effective in decreasing total, inflammatory, and non-inflammatory lesion counts along with well tolerability in Asian patients with mild to moderate acne vulgaris.

Cited by 24 publications

References 23 publications

Clindamycin phosphate 1·2%-benzoyl peroxide 3·0% fixed-dose combination gel has an effective and acceptable safety and tolerability profile for the treatment of acne vulgaris in Japanese patients: a phase III, multicentre, randomised, single-blinded, acti

Clindamycin phosphate 1·2%-benzoyl peroxide 3·0% fixed-dose combination gel has an effective and acceptable safety and tolerability profile for the treatment of acne vulgaris in Japanese patients: a phase III, multicentre, randomised, single-blinded, acti

Do tutorials on application method enhance adapalene–benzoyl peroxide combination gel tolerability in the treatment of acne?

Systematic review on the rapidity of the onset of action of topical treatments in the therapy of mild-to-moderate acne vulgaris

Contact Info

Product

Resources

About